Marina W. H. Shen

发表

Inhibition of Cytosolic Phospholipase A 2 a: Hit to Lead Optimization

John C. McKew, S. Khor, J. D. Clark, 2006 .

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

M. Leach, Takao Shimizu, J. D. Clark, 2008, Journal of Neuroimmunology.

Cytosolic phospholipase A2α–deficient mice are resistant to experimental autoimmune encephalomyelitis

J. Leonard, M. Leach, Takao Shimizu, 2005, The Journal of experimental medicine.

Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties.

J. D. Clark, J. McKew, J. Xiang, 2009, Bioorganic & medicinal chemistry.

Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors.

J. D. Clark, J. McKew, E. A. Murphy, 2008, Analytical biochemistry.

Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.

David R. Anderson, S. Wright, V. Rao, 2017, Journal of medicinal chemistry.

Cytosolic phospholipase A 2 – deficient mice are resistant to experimental autoimmune encephalomyelitis

J. Leonard, M. Leach, Takao Shimizu, 2005 .

Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.

J. D. Clark, M. Hegen, J. McKew, 2008, Journal of medicinal chemistry.

The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid

J. D. Clark, J. McKew, W. Duan, 2011, Neuropharmacology.

1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2α inhibitors

D. Joseph-McCarthy, J. McKew, A. Gopalsamy, 2006 .

Structure–activity relationships of indole cytosolic phospholipase A2α inhibitors: substrate mimetics

J. Alvarez, D. Joseph-McCarthy, J. D. Clark, 2003 .

Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.

J. D. Clark, J. McKew, W. Abraham, 2008, Bioorganic & medicinal chemistry.

A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening.

J. D. Clark, E. A. Murphy, Yuren Wang, 2005, Analytical biochemistry.

Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.

J. McKew, E. A. Murphy, Xingwei Xu, 2009, Journal of medicinal chemistry.

Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase Α2α

S. Khor, J. D. Clark, J. McKew, 2007 .

Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha.

S. Khor, J. McKew, M. S. Ku, 2007, Journal of medicinal chemistry.

Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.

D. Boschelli, V. Rao, E. A. Murphy, 2014, Bioorganic & medicinal chemistry letters.

Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization.

S. Khor, J. McKew, A. Mahadevan, 2006, Journal of medicinal chemistry.

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

M. Leach, Takao Shimizu, J. D. Clark, 2008, Journal of Neuroimmunology.

Cytosolic phospholipase A2α–deficient mice are resistant to experimental autoimmune encephalomyelitis

J. Leonard, M. Leach, Takao Shimizu, 2005, The Journal of experimental medicine.